SVB Wealth LLC Makes New $4.07 Million Investment in Pfizer Inc. $PFE

SVB Wealth LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 168,082 shares of the biopharmaceutical company’s stock, valued at approximately $4,074,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Westbourne Investments Inc. purchased a new stake in shares of Pfizer during the first quarter valued at about $2,411,000. Bourne Lent Asset Management Inc. boosted its stake in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares in the last quarter. Strs Ohio purchased a new position in Pfizer in the first quarter worth $49,968,000. IFM Investors Pty Ltd boosted its holdings in Pfizer by 3.8% in the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after acquiring an additional 41,263 shares in the last quarter. Finally, Intrua Financial LLC grew its position in Pfizer by 17.4% during the 1st quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock worth $1,986,000 after purchasing an additional 11,643 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $26.03 on Monday. The firm has a market cap of $147.97 billion, a price-to-earnings ratio of 15.13 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company has a 50 day moving average price of $25.17 and a 200-day moving average price of $24.69. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 7th were given a dividend of $0.43 per share. The ex-dividend date was Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.